Pleural mesothelioma: little evidence, still time to do trials.
about
Malignant mesotheliomaMDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.BTS statement on malignant mesothelioma in the UK, 2007.Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexedPemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.Current chemotherapeutic treatment of malignant pleural mesothelioma.Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma.Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesotheliomaRadical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?Malignant mesothelioma: current status and perspective in Japan and the world.Malignant pleural mesothelioma: current and future perspectivesA possible association between aprotinin and improved survival after radical surgery for mesothelioma.Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position.The function, mechanisms, and role of the genes PTEN and TP53 and the effects of asbestos in the development of malignant mesothelioma: a review focused on the genes' molecular mechanisms.Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of life-relation to chemotherapy, radiotherapy, and alternative therapies.Local and systemic therapies for malignant pleural mesothelioma.[Malignant pleural mesothelioma: multidisciplinary experience in a public tertiary hospital].Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.Heterogeneous nuclear ribonucleoprotein B1 expression in malignant mesothelioma.Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance.The need for randomized trials in mesothelioma: let's walk the talk.Malignant mesothelioma: Canadian perspective and research directions.BAP1 protein is a progression factor in malignant pleural mesothelioma.Dusted community: piloting a virtual peer-to-peer support community for people with an asbestos-related diagnosis and their families.Simultaneous presentation of myasthenia gravis and mesothelioma.Palliative intracavitary carboplatin therapy in a cat with suspected pleural mesothelioma.
P2860
Q21202901-BF22FF34-76B6-42E1-8BDB-9D259F5AB4F1Q27853125-B9C548D9-9EE7-4B1C-9C59-2DCAEC6741FCQ30478994-27530B21-C5B9-4C8D-B55D-8F6D15C3F620Q33274781-656E38B9-7ECA-46F5-83D4-811912630326Q33379936-1796F5AE-06FE-4C18-ACC8-41C7151E0094Q35141809-BE32E398-0D80-4EDD-BFB8-09A1AEA875BAQ35967314-6CCA8C59-BE33-45D8-880D-75C284163C5BQ36755228-FE876706-4AF9-4576-AB1F-C70C53D38F70Q36821171-74CFDA9D-2CD9-471C-87B1-E2B7EDF0D8E0Q37090803-F43595AB-92B4-45C3-B33B-B4133FDCE2D0Q37209613-B349586B-3177-4C08-8C23-B4051F78A5A4Q37217764-BF5A1AF1-9F70-4982-ACAE-9BB0BC4ADA2FQ37364652-461CDA8E-E3C7-439A-9C96-FCFC5F31C4AAQ37552639-342CCE49-966C-4111-8D05-3EFB013BB028Q38148036-AE427274-EBE9-4136-AFE8-BCA88CD49403Q38195607-432A7921-6EC4-4991-8591-6F9B5BAAED45Q38255347-8CF9AB35-1C18-4E0F-A8B2-9C72CAC6F7A3Q38443843-5515FC52-E52F-4D06-819E-78ECC772B7F7Q38748263-C9DA73C8-261F-4526-8410-729E555FC10FQ40238588-31B34012-FDC0-4052-8E89-F2556103D6F2Q40438301-91F57D61-C2DC-48AB-BF20-F174BB06E22AQ42575346-5CD66B8A-D4E8-4C75-8F05-A49D9D13BFFCQ42995477-FD94E3B4-DA8F-4B6C-984D-B9F8062DAE53Q47098675-88B08CD6-9CDC-4539-9714-67303BA406BAQ47734004-1963FAB2-6485-4680-BB64-945B19507E91Q51838655-4BFA6F3E-18E7-41BF-B962-BC159CE8CCA6Q53540093-0EAE0654-9BA3-4FCF-8F54-0F81C17046BDQ53621359-479926F5-20B3-4AC5-90D6-B7E6B2CD916F
P2860
Pleural mesothelioma: little evidence, still time to do trials.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Pleural mesothelioma: little evidence, still time to do trials.
@ast
Pleural mesothelioma: little evidence, still time to do trials.
@en
type
label
Pleural mesothelioma: little evidence, still time to do trials.
@ast
Pleural mesothelioma: little evidence, still time to do trials.
@en
prefLabel
Pleural mesothelioma: little evidence, still time to do trials.
@ast
Pleural mesothelioma: little evidence, still time to do trials.
@en
P1433
P1476
Pleural mesothelioma: little evidence, still time to do trials.
@en
P2093
Artyom Sedrakyan
Tom Treasure
P304
P356
10.1016/S0140-6736(04)17108-0
P407
P577
2004-09-01T00:00:00Z